Financial News
All News about Royalty Pharma Plc Cl A
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_3659.jpeg?width=1200&height=800&fit=crop)
Stocks That Hit 52-Week Lows On Tuesday
February 28, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Preview: Royalty Pharma's Earnings
February 14, 2023
Via Benzinga
Ominous Death Cross Forms On Royalty Pharma's Chart
January 10, 2023
Via Benzinga
Looking Into Royalty Pharma's Return On Capital Employed
December 06, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/02/28/image20.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/02/27/image11.jpg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
Royalty Pharma Reports Q4 and Full Year 2022 Results
February 15, 2023
From Royalty Pharma plc
Via GlobeNewswire
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
Royalty Pharma to Present at Upcoming Investor Conferences
February 09, 2023
From Royalty Pharma plc
Via GlobeNewswire
![](https://cdn.benzinga.com/files/images/story/2023/01/31/biotech_shutter.jpg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://www.valuewalk.com/wp-content/uploads/2022/09/Telehealth_1663693190-768x423.jpg)
Five Best And Worst Performing Healthcare Stocks In December 2022
January 22, 2023
Via Talk Markets
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
Royalty Pharma Announces Dividend Increase
January 09, 2023
From Royalty Pharma plc
Via GlobeNewswire
![](https://www.globenewswire.com/Content/Images/intrado.png)
From Royalty Pharma plc
Via GlobeNewswire
![](https://g.foolcdn.com/editorial/images/713046/buffett9-tmf.jpg)
![](https://www.globenewswire.com/Content/Images/intrado.png)
Royalty Pharma Announces Expansion of Senior Leadership Team
December 15, 2022
From Royalty Pharma plc
Via GlobeNewswire
![](https://www.globenewswire.com/Content/Images/intrado.png)
Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
November 28, 2022
From Royalty Pharma plc
Via GlobeNewswire
![](https://www.globenewswire.com/Content/Images/intrado.png)
![](https://mms.businesswire.com/media/20221109005596/en/523535/5/ah_logo_cmyk.jpg)
![](https://www.globenewswire.com/Content/Images/intrado.png)
Royalty Pharma Reports Third Quarter 2022 Results
November 08, 2022
From Royalty Pharma plc
Via GlobeNewswire
![](https://www.globenewswire.com/Content/Images/intrado.png)
![](https://g.foolcdn.com/editorial/images/705084/worried.jpg)
![](https://www.globenewswire.com/Content/Images/intrado.png)
Royalty Pharma Declares Fourth Quarter 2022 Dividend
October 17, 2022
From Royalty Pharma plc
Via GlobeNewswire
![](https://cdn.benzinga.com/files/images/story/2022/10/14/test-gcd00d1810_1280.jpg?width=1200&height=800&fit=crop)
![](https://www.globenewswire.com/Content/Images/intrado.png)
Royalty Pharma Announces Expansion of Leadership Team
October 12, 2022
From Royalty Pharma plc
Via GlobeNewswire
![](https://www.globenewswire.com/Content/Images/intrado.png)
![](https://cdn.benzinga.com/files/images/story/2022/09/19/aapharma_14.png?width=1200&height=800&fit=crop)
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
September 19, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.